BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38320426)

  • 1. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
    Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
    Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.
    Desantis J; Bazzacco A; Eleuteri M; Tuci S; Bianconi E; Macchiarulo A; Mercorelli B; Loregian A; Goracci L
    Eur J Med Chem; 2024 Mar; 268():116202. PubMed ID: 38394929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
    Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
    J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT.
    Cheng J; He S; Xu J; Huang M; Dong G; Sheng C
    J Med Chem; 2022 Dec; 65(23):15725-15737. PubMed ID: 36442664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
    Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
    ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
    Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
    J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Optimization of Decoy Oligonucleotide-Based PROTAC That Degrades the Estrogen Receptor.
    Naganuma M; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioconjug Chem; 2023 Oct; 34(10):1780-1788. PubMed ID: 37736001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
    Wang C; Zhang Y; Chen W; Wu Y; Xing D
    Mol Cancer; 2024 May; 23(1):110. PubMed ID: 38773495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
    Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
    J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment.
    Xie B; Xu B; Xin L; Wei Y; Guo X; Dong C
    Bioorg Chem; 2023 Aug; 137():106590. PubMed ID: 37163809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target protein localization and its impact on PROTAC-mediated degradation.
    Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
    Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
    Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
    Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α.
    Jiang Y; Deng Q; Zhao H; Xie M; Chen L; Yin F; Qin X; Zheng W; Zhao Y; Li Z
    ACS Chem Biol; 2018 Mar; 13(3):628-635. PubMed ID: 29271628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACS: A technology with a gold rush-like atmosphere.
    Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
    Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
    Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
    Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.